Macro photograph of a high-precision automated laboratory pipette dispensing clear liquid into a microplate, cool bright blue and white lighting, professional depth of field
Macro photograph of a high-precision automated laboratory pipette dispensing clear liquid into a microplate, cool bright blue and white lighting, professional depth of field
Inquire About Partnerships
Clinical Pipeline

Targeting cellular bioenergetics directly

Our clinical-stage pipeline introduces controlled mitochondrial uncoupling to address metabolic dysfunction-associated steatohepatitis and obesity while preserving essential lean muscle mass.

Therapeutic Portfolio

Clinical Development Progress

Our candidates target distinct metabolic pathways to achieve systemic fat reduction and tissue-specific resolution of metabolic disease.

Lead Asset • Phase 2
Lead Asset • Phase 2
Investigational • Phase 1

HU6 for Obesity

HU6 for MASH

RV-8451 Therapy

Evaluating controlled metabolic acceleration to preserve lean mass during significant weight reduction.

Targeting liver fat reduction and inflammation resolution through direct mitochondrial pathways.

An oral GLP-1 candidate designed to expand our metabolic disease platform with complementary mechanisms.

Phase 2a

Active Trial Progress

Phase 2b

Patient Enrollment

Phase 1

In Development

A 3D molecular visualization of a mitochondrial inner membrane with active protein structures, glowing teal accents on a dark blue background, highly technical
A 3D molecular visualization of a mitochondrial inner membrane with active protein structures, glowing teal accents on a dark blue background, highly technical
Review Phase 2a Results
Primary Candidate

Controlled Mitochondrial Uncoupling

HU6 is a first-in-class oral small molecule that safely accelerates natural cellular energy consumption, reducing systemic fat while protecting vital muscle tissues.

Phase 2a clinical data demonstrated statistically significant reductions in liver fat and visceral adipose tissue. Unlike traditional therapies, HU6 achieves these outcomes without suppressing appetite or causing muscle wasting.

-30%

Liver Fat Reduction

100%

Lean Mass Preservation

Close-up of a modern laboratory bioreactor with liquid flowing through sterile tubes, bright clinical setting, soft blue and white lighting, sharp focus
Close-up of a modern laboratory bioreactor with liquid flowing through sterile tubes, bright clinical setting, soft blue and white lighting, sharp focus
Request Clinical Data
Next-Generation Platform

Investigational Oral GLP-1

RV-8451 expands our cardiometabolic portfolio as a highly selective oral GLP-1 receptor agonist. It is engineered to provide a stable, bioavailable alternative to injectable therapies.

By combining RV-8451 with our mitochondrial uncoupling platform, we aim to deliver comprehensive, highly tolerable therapeutic options for complex metabolic conditions.